Sorafenib (SRF) is a well-known tyrosine kinase inhibiting anticancer drug which iseffectual against multiple carcinomas especially gastric cancers by targeting the Ras/Raf/Mek/Erk cascade pathway and blocking the tumor cell proliferation. In the present work, we have reduced graphene oxide (GO) in presence of sorafenib using ascorbic as green reducing agent for the treatment of gastric cancers. Sorafenib reduced graphene oxide (SRGO) were obtained with a transparent and smoothmorphology. The drug loaded SRGO has presented significant cytotoxic effect against SGC7901 cancer cells when compared to that of the free SRF and blank NPs in the equivalent concentrations. Additionally, from the Hoechst 33382 staining study it was evident that the cells in untreated groups remained intact with its round shape and intact nuclei while the SRGO treated cells have shown a cell transformation with apoptosis of gastric cancer cell lines. Based on these results, we can conclude that SRGO might extend an enormous prospective in the treatment of gastric cancers.
Keywords: Gastric cancer; Graphene; Graphene oxide; Sorafenib.
Copyright © 2018. Published by Elsevier B.V.